BIOHARVEST SCIENCES INC.
No SEC Form 4 filings for $BHST in the last 30 days.
See all $BHST insider activity →BioHarvest Sciences reported a Q2 2026 earnings call focused on shifting capital from D2C to CDMO. It secured a CDMO manufacturing and supply deal for a rare fragrance, targeting $20m to $30m revenue in 2027-2028 and $180m over five years, with limited production in H1 2027. 2026 revenue guidance was cut to $37m-$40m, and it expects CDMO EBITDA loss of $1.5m-$2.5m and consolidated EBITDA breakeven in 2027.
BioHarvest Sciences (BHST) reported Q2 revenue of $8.8M, up 3.8% y/y, with net loss of $3.7M ($0.17/sh) versus $4.1M ($0.24/sh) a year earlier. Operating expenses rose to $7.6M. Cash and equivalents plus deposits were $16.25M at June 30. It tightened CDMO guidance to $4M-$5M and cut VINIA guidance to $33M-$35M, and signed a UAE customer deal for 20 tons of a fragrance ingredient starting as early as H1 2027.
BioHarvest Sciences Inc (NASDAQ: BHST) reported Q2 2026 revenue of $8.8 million, up 3.8% year over year, with 58% gross margin. The company said it secured its first CDMO manufacturing and supply agreement for a UAE fragrance ingredient, targeting up to 20 tons over two years, with limited production possibly starting in H1 2027. It also received a $1.4M Israel Innovation Authority grant.
Over the past 7 days, alphai's AI scored 2 news stories mentioning BHST (BIOHARVEST SCIENCES INC.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent BHST coverage spans financial news and earnings.
BioHarvest Sciences reported a Q2 2026 earnings call focused on shifting capital from D2C to CDMO. It secured a CDMO manufacturing and supply deal for a rare fragrance, targeting $20m to $30m revenue in 2027-2028 and $180m over five years, with limited production in H1 2027. 2026 revenue guidance was cut to $37m-$40m, and it expects CDMO EBITDA loss of $1.5m-$2.5m and consolidated EBITDA breakeven in 2027.
Guidance tightening plus a scaled manufacturing agreement improves near-term revenue visibility, but EBITDA losses remain expected and VINIA D2C guidance is lowered.
The new CDMO manufacturing agreement is a concrete step toward recurring manufacturing revenue, but near-term impact is likely limited until early 2027 production begins.
The grant provides incremental, non-dilutive funding for an AI-driven R&D initiative, supporting runway and potentially improving development efficiency.
The grant adds non-dilutive funding and supports an AI/ML R&D initiative, which can improve development efficiency but is milestone- and revenue-dependent.
alphai scores every news story that mentions BHST with an AI model for sentiment and relevance, and aggregates insider trades from BIOHARVEST SCIENCES INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
BioHarvest Sciences reported a Q2 2026 earnings call focused on shifting capital from D2C to CDMO. It secured a CDMO manufacturing and supply deal for a rare fragrance, targeting $20m to $30m revenue in 2027-2028 and $180m over five years, with limited production in H1 2027. 2026 revenue guidance was cut to $37m-$40m, and it expects CDMO EBITDA loss of $1.5m-$2.5m and consolidated EBITDA breakeven in 2027.
6 min readBioHarvest Sciences (BHST) reported Q2 revenue of $8.8M, up 3.8% y/y, with net loss of $3.7M ($0.17/sh) versus $4.1M ($0.24/sh) a year earlier. Operating expenses rose to $7.6M. Cash and equivalents plus deposits were $16.25M at June 30. It tightened CDMO guidance to $4M-$5M and cut VINIA guidance to $33M-$35M, and signed a UAE customer deal for 20 tons of a fragrance ingredient starting as early as H1 2027.
4 min readBioHarvest Sciences Inc (NASDAQ: BHST) reported Q2 2026 revenue of $8.8 million, up 3.8% year over year, with 58% gross margin. The company said it secured its first CDMO manufacturing and supply agreement for a UAE fragrance ingredient, targeting up to 20 tons over two years, with limited production possibly starting in H1 2027. It also received a $1.4M Israel Innovation Authority grant.
6 min readBioHarvest Sciences (NASDAQ:BHST) said it received a 4.33 million NIS (about $1.4 million) grant from Israel Innovation Authority to fund an AI and computer-vision initiative for its plant cell culture programs. The non-dilutive, zero-interest loan supports integrating data science, chemo-informatics and digital sensing to build a computational discovery engine. Repayment depends on commercial milestones and future revenues.
3 min readBioHarvest Sciences (NASDAQ: BHST) said the Israel Innovation Authority approved a 4.33 million NIS (about $1.4 million) non-dilutive, zero-interest grant to fund an AI and data-science initiative for plant-cell culture optimization. The company said the second IIA grant this year supports predictive machine learning and digital sensing, with repayment tied to commercial milestones.
3 min readBioHarvest Sciences Inc. (BHST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2 min readBioHarvest Sciences Inc. (BHST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
2 min read
